Flag of the European Union EU Clinical Trials Register Help

Clinical trials for interferon gamma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title:
    Active substance: INTERFERON GAMMA (1B
    Study summary document link (including results):
    View full study record
    Document reference: 47176
    Study title: 107.162, 107.235 - A Population pharmacokinetic analysis for meloxicam in pediatric juvenile rheumatoid arthritis patients – A combined analysis of pharmacokinetic data obtained in studies 107.162 and 107.235
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30200
    Study title: 137158 - Clinical efficacy of recombinant human interferon-gamma in chronic granulomatous disease.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30192
    Study title: 137163 - To study the effect duration of two different doses of IFN-gamma in patients with chronic granulomatous disease (CGD) on functional responses of neutrophils (PMN).
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30193
    Study title: 137177 - The immunomodulatory impact of Imukin (IFNgamma-1b) on clinical and laboratory data in the treatment of atopic dermatitis.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30194
    Study title: A phase III randomized, controlled open label trial of actimmune (Interferon gamma-1b, rIFN-alpha1b) in patients with severe, congenital (malignant) osteopetrosis.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30205
    Study title: An open phase III follow-up (5 years) trial of recombinant human interferon gamma-1b in patients with chronic granulomatous disease (CGD) to evaluate safety and efficacy of long-term interferon gamma-1b treatment - 5-year-follow-up safety report.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30191
    Study title: BL 103836,GCGD4-002 - Long-term safety and efficacy of Actimmune therapy in children with chronic granulomatous disease (CGD): Summary of data from the National Institutes of Health cohort in children initiating Actimmune prior to 1 year of age and prior to 3 years of age, respectively.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30198
    Study title: Clinical efficacy of recombinant human interferon-gamma in chronic granulomatous disease.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30202
    Study title: EBI 4.20,IP 137.3,137.3 - Interferon gamma-1b (IF-RC 1001 XX G): Safety, Efficacy and Pharmacokinetics of 0.1 mg/sqm, 0.25 mg/sqm and 0.5 mg/sqm Interferon gamma-1b for 2 or more Weeks Subcutaneaously Administered to Patients with Lymphomas, Plasmocytomas and Solid Tumors.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30199
    Study title: I0016g(A),CH 9903,137.41 - An open phase III follow-up (5 years) trial of recombinant human interferon gamma-1b in patients with chronic granulomatous disease (CGD) to evaluate safety and efficacy of long-term interferon gamma-1b treatment - 5-year-follow-up safety report.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30196
    Study title: I0286n - Post marketing surveillance study of Actimmune (recombinant human interferon gamma-Ib) in patients with chronic granulomatous disease.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30195
    Study title: I0681s - A phase III randomized, controlled open label trial of actimmune (Interferon gamma-1b, rIFN-alpha1b) in patients with severe, congenital (malignant) osteopetrosis.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30197
    Study title: Interferon gamma-1b (IF-RC 1001 XX G): Safety, Efficacy and Pharmaco- kinetics of 0.1 mg/sqm, 0.25 mg/sqm and 0.5 mg/sqm Interferon gamma-1b for 2 or more Weeks Sub- cutaneaously Administered to Patients with Lympho- mas, Plasmo- cytomas and Solid Tumors.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30201
    Study title: Long-term safety and efficacy of Actimmune therapy in children with chronic granulomatous disease (CGD): Summary of data from the National Institutes of Health cohort in children initiating Actimmune prior to 1 year of age and prior to 3 years of age, respectively.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30206
    Study title: Long-term safety and efficay of Actimmune therapy in young children with chronic granulomatous disease (CGD): An integrated summary of data extracted from Studies I0016g, I0016g(A),I0034g, and I0286n in children initiating Actimmune therapy prior to 1 year of age and prior to 3 years of age, respectively.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30207
    Study title: Post marketing surveillance study of Actimmune (recombinant human interferon gamma-Ib) in patients with chronic granulomatous disease.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30190
    Study title: The immunomodulatory impact of Imukin (IFNgamma-1b) on clinical and laboratory data in the treatment of atopic dermatitis.
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30204
    Study title: To study the effect duration of two different doses of IFN-gamma in patients with chronic granulomatous disease (CGD) on functional responses of neutrophils (PMN).
    Active substance: INTERFERON GAMMA (1B)
    Study summary document link (including results):
    View full study record
    Document reference: 30203
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 08:28:53 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA